Valuation: Evolus, Inc.

Market Cap 397M 349M 326M 299M 560M 38.04B 573M 3.86B 1.51B 18.82B 1.49B 1.46B 65.07B P/E 2026 *
-12.1x
P/E 2027 * -41.1x
Enterprise Value 524M 461M 430M 395M 738M 50.2B 757M 5.1B 1.99B 24.84B 1.97B 1.93B 85.88B EV / Sales 2026 *
1.59x
EV / Sales 2027 * 1.36x
Free-Float
83.36%
Yield 2026 *
-
Yield 2027 * -
1 week+2.23%
Current month-14.10%
1 month-15.63%
3 months+17.08%
6 months+33.74%
Current year-4.29%
1 week 5.02
Extreme 5.024
5.54
1 month 4.74
Extreme 4.74
6.29
3 years 3.36
Extreme 3.36
16.1
5 years 3.36
Extreme 3.36
16.1
Manager TitleAgeSince
Chief Executive Officer 48 2018-05-05
Director of Finance/CFO 48 2025-09-07
Chief Operating Officer - 2022-08-31
Director TitleAgeSince
Chairman 63 2017-12-31
Director/Board Member 71 2018-02-11
Director/Board Member 48 2018-05-05
Change 5-day change 1-year change 3-year change Capi.($)
+2.61%+2.23%-33.97%-42.68% 397M
-0.87%+4.04%+58.60%+163.92% 1,079B
-0.45%+3.87%+57.95%+52.18% 640B
+0.04%+3.95%+37.69%+74.54% 465B
-2.18%+1.23%+36.29%+30.75% 353B
-1.47%+0.05%+34.41%+40.24% 301B
-2.40%+0.90%+11.34%+14.45% 271B
-1.58%+3.70%+2.20%-39.18% 228B
-1.39%+5.90%+27.70%+64.00% 209B
-1.18%+1.83%+16.20%+72.69% 165B
Average -1.64%+4.83%+24.84%+43.09% 412.19B
Weighted average by Cap. -1.80%+4.86%+41.24%+77.69%

Financials

2026 *2027 *
Net sales 330M 290M 271M 249M 466M 31.65B 477M 3.21B 1.26B 15.66B 1.24B 1.21B 54.15B 388M 341M 318M 292M 546M 37.13B 560M 3.77B 1.47B 18.37B 1.46B 1.42B 63.52B
Net income -33.31M -29.27M -27.32M -25.07M -46.93M -3.19B -48.09M -324M -127M -1.58B -125M -122M -5.46B -10.56M -9.28M -8.66M -7.95M -14.88M -1.01B -15.25M -103M -40.17M -501M -39.65M -38.79M -1.73B
Net Debt 127M 112M 104M 95.6M 179M 12.16B 183M 1.24B 483M 6.02B 477M 466M 20.81B 132M 116M 108M 99.36M 186M 12.64B 191M 1.28B 502M 6.26B 496M 485M 21.63B
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
-
Date Price Change
26-07-30 5.226 +0.19%
26-07-29 €5.216 -4.05%
26-07-28 €5.436 +0.15%
26-07-27 €5.428 +3.00%
26-07-24 €5.270 +0.57%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.030USD
Average target price
14.67USD
Spread / Average Target
+143.23%

Quarterly revenue - Rate of surprise